Analysts Set MiMedx Group, Inc (NASDAQ:MDXG) Target Price at $8.50

Shares of MiMedx Group, Inc (NASDAQ:MDXG) have received an average recommendation of “Moderate Buy” from the seven research firms that are covering the stock, MarketBeat Ratings reports. One analyst has rated the stock with a sell recommendation and six have issued a buy recommendation on the company. The average 12-month price target among analysts that have updated their coverage on the stock in the last year is $8.4286.

A number of analysts have commented on the stock. Seaport Research Partners cut shares of MiMedx Group to a “neutral” rating in a report on Monday, August 17th. Citizens Jmp dropped their price target on shares of MiMedx Group from $7.00 to $6.00 and set a “market outperform” rating on the stock in a research note on Thursday, April 30th. Weiss Ratings reissued a “sell (d)” rating on shares of MiMedx Group in a research report on Thursday, August 13th. Cantor Fitzgerald restated an “overweight” rating and issued a $8.00 price objective on shares of MiMedx Group in a research note on Monday, August 17th. Finally, Wall Street Zen lowered MiMedx Group from a “hold” rating to a “sell” rating in a research note on Saturday, August 1st.

Institutional Trading of MiMedx Group

A number of hedge funds and other institutional investors have recently bought and sold shares of the stock. Kemnay Advisory Services Inc. purchased a new position in shares of MiMedx Group during the 4th quarter valued at about $48,000. Sunbelt Securities Inc. purchased a new stake in MiMedx Group in the 1st quarter worth approximately $42,000. Jain Global LLC purchased a new stake in MiMedx Group in the 4th quarter worth approximately $73,000. E Fund Management Co. Ltd. bought a new stake in MiMedx Group during the 2nd quarter worth approximately $45,000. Finally, Virtu Financial LLC bought a new stake in MiMedx Group during the 4th quarter worth approximately $78,000. Hedge funds and other institutional investors own 79.15% of the company’s stock.

MiMedx Group Price Performance

MDXG stock opened at $4.33 on Monday. The company has a market cap of $631.14 million, a price-to-earnings ratio of 108.28 and a beta of 1.45. The company has a debt-to-equity ratio of 0.07, a quick ratio of 4.79 and a current ratio of 5.33. The business’s 50-day moving average is $4.11 and its two-hundred day moving average is $4.11. MiMedx Group has a fifty-two week low of $3.03 and a fifty-two week high of $7.97.

MiMedx Group (NASDAQ:MDXG) last released its quarterly earnings results on Wednesday, July 29th. The company reported ($0.05) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.05). MiMedx Group had a return on equity of 12.09% and a net margin of 1.76%.The business had revenue of $64.36 million during the quarter, compared to the consensus estimate of $63.46 million. As a group, analysts forecast that MiMedx Group will post -0.1 earnings per share for the current year.

About MiMedx Group

MiMedx Group, Inc is a biopharmaceutical company focused on the development, manufacture and marketing of regenerative biomaterial products derived from human placental tissues. The company’s core mission centers on harnessing the extracellular matrix and growth factors within amniotic and chorionic membranes to support wound healing and surgical applications. MiMedx’s product line leverages proprietary purification processes designed to retain native tissue properties while ensuring sterility and safety.

MiMedx’s principal offerings include amnion/chorion allografts branded under names such as EpiFix® and AmnioFix®, which are indicated for the treatment of acute and chronic wounds—including diabetic foot ulcers, venous leg ulcers and surgical site repair.